1
|
Bosc D. Click Reactions in Medicinal Chemistry. Pharmaceuticals (Basel) 2023; 16:1361. [PMID: 37895832 PMCID: PMC10610155 DOI: 10.3390/ph16101361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 09/23/2023] [Indexed: 10/29/2023] Open
Abstract
Two decades after K [...].
Collapse
Affiliation(s)
- Damien Bosc
- Institute Pasteur Lille, U1177-Drugs and Molecules for Living Systems, Univsity Lille, Inserm, F-59000 Lille, France
| |
Collapse
|
2
|
Hou XX, Wu ZY, Zhan A, Gao E, Mao LF, Wang HL, Yang JX. Synthesis and activity study of novel N,N-diphenylurea derivatives as IDO1 inhibitors. Front Chem 2023; 11:1222825. [PMID: 37408559 PMCID: PMC10318132 DOI: 10.3389/fchem.2023.1222825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Accepted: 05/25/2023] [Indexed: 07/07/2023] Open
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) has attracted much attention in the field of cancer immunotherapy as an immunomodulatory enzyme. To identify potential IDO1 inhibitors, a novel series of compounds with N,N-diphenylurea and triazole structures were synthesized. The designed compounds underwent organic synthesis, and subsequent enzymatic activity experiments targeting IDO1 confirmed their activity at the molecular level. These experiments provided validation for the efficacy of the designed compounds in inhibiting IDO1, compound 3g exhibited an IC50 value of 1.73 ± 0.97 μM. Further molecular docking study further explained the binding mode and reaction potential of compound 3g with IDO1. Our research has resulted in a series of novel IDO1 inhibitors, which is beneficial to the development of drugs targeting IDO1 in numerous cancer diseases.
Collapse
Affiliation(s)
- Xi-Xi Hou
- Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
| | - Zi-Yuan Wu
- Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
- School of Nursing, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China
| | - An Zhan
- Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
- School of Nursing, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China
| | - En Gao
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China
- State Key Laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China
| | - Long-Fei Mao
- Henan Wanliu Biotechnology Co., Ltd., Luoyang, China
| | - Hui-Li Wang
- UNC Hospital, Chapel Hill, NC, United States
| | - Jian-Xue Yang
- Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
- School of Nursing, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, China
| |
Collapse
|